Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis
Breast Cancer Research and Treatment · 2026-06 · 217 (2)
DOI: 10.1007/s10549-026-07960-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 12.06.2026. Verfasst von Caio Dabbous de Liz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Paraná, Rede Américas, Maringá, Paraná, Brazil. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Breast Neoplasms, Ovary, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Federal Do Rio De Janeiro.
Abstract (Originalsprache)
Purpose
Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) improves outcomes in premenopausal women with hormone receptor–positive (HR +) breast cancer (BC), most commonly using monthly administration. The potential equivalence of 3-monthly (3 M) versus monthly (1 M) schedules has been suggested but remains uncertain.
Methods
We performed a systematic review and meta-analysis of interventional studies comparing 3 M and 1 M GnRHa regimens in premenopausal women with HR + BC receiving endocrine therapy. Outcomes included ovarian escape (OE), mean estradiol (E2) levels, disease-free survival (DFS), progression-free survival (PFS), and adverse events. Subgroup analyses were performed by estradiol assay type, and a sensitivity analysis restricted to RCTs.
Results
Fifteen studies comprising 4,324 patients were included, of whom 2,098 (48%) received a 3 M regimen. The pooled OE was 10% and showed no significant difference between schedules (RR 0.86; 95% CI 0.60–1.22; p = 0.39). Ultrasensitive assays yielded higher OE detection (31%) without inter-regimen differences (RR 0.90; 95% CI 0.38–2.14). Mean E2 concentrations at 12 weeks were similar (MD 1.36 pg/mL; 95% CI –3.66 to 6.38), with consistent findings in RCT-only analyses (MD –1.77 pg/mL; 95% CI –5.71 to 2.17). DFS (RR 1.02; 95% CI 0.67–1.56) and PFS (RR 0.86; 95% CI 0.72–1.04) were also comparable. No clinically relevant differences were observed in reported safety outcomes.
Conclusion
3 M GnRHa achieved OFS efficacy comparable to 1 M regimens, with no meaningful differences in survival or safety. The findings support 3 M GnRHa as a valid and practical alternative for OFS in appropriately selected premenopausal women with HR + BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Paraná, Rede Américas, Maringá, Paraná, Brazil.
- Universidade Federal Do Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil. pedroreis@ufrj.br.
- Université Paris Cité, Paris, France.
- Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil.
- Universidade Federal da Paraíba (UFPB), João Pessoa, Paraíba, Brazil.
- Oncoclínicas, Salvador, Bahia, Brazil.
Förderung
- Universidade Federal Do Rio De Janeiro
Zitieren
APA
de Liz, C. D., Reis, P. C. A., Blanchard-Cavagis, E. R., Diniz, I. C., Brito, H. C., & Visani, F. L. V. (2026). Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 217(2). https://doi.org/10.1007/s10549-026-07960-2
Vancouver
de Liz CD, Reis PCA, Blanchard-Cavagis ER, Diniz IC, Brito HC, Visani FLV. Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 2026;217(2). doi:10.1007/s10549-026-07960-2
BibTeX
@article{deLiz2026,
author = {de Liz, Caio Dabbous and Reis, Pedro C Abrahão and Blanchard-Cavagis, Ellen R and Diniz, Isabela C and Brito, Heloísa Carneiro and Visani, Filipe Luis Vasconcelos},
title = {Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis},
journal = {Breast Cancer Research and Treatment},
year = {2026},
volume = {217},
number = {2},
doi = {10.1007/s10549-026-07960-2}
}
EUVIMED